How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer

Licensing

Nanobiotix (NBTX) set out to fundamentally change a century-old mainstay in battling cancer. Six years after the biotech company went public, investors are paying closer attention, sending the top-notch biotech stock to multiple record highs in 2026. Unlike its peers in the biotech space, the Paris-based company and Johnson & Johnson (JNJ) partner isn't leveraging biology or chemistry, says Chief…